Table 1.
Research resource identifier | Cell line collections | Disease |
VHL status; SETD2 status (COSMIC) + for wild-type gene − for mutated gene |
References | |
---|---|---|---|---|---|
ACHN | RRID:CVCL_1067 | ATCC® CRL-1611™; ECACC 88100508 |
Renal cell carcinoma, derived from metastatic site, male, 22Y |
VHL+; SETD2+ | 33,55,56 |
Caki-1 | RRID:CVCL_0234 | ATCC® HTB-46™; DSMZ ACC-731 |
Renal cell carcinoma, derived from metastatic site, male, 49Y |
VHL+; SETD2− | 33,56,57 |
Caki-2 | RRID:CVCL_0235 | ATCC® HTB-47™; DSMZ ACC-54; ECACC 93120819 |
Renal cell carcinoma, derived from primary tumor site, male, 69Y |
VHL−; SETD2+ | 33,57 |
A498 | RRID:CVCL_1056 | ATCC® HTB-44™; DSMZ ACC-55 |
Renal cell carcinoma, derived from primary tumor site, male, 52Y |
VHL−; SETD2− | 33,56,57 |
RCC-FG2 | RRID:CVCL_5873 | CLS #300249 |
Renal cell carcinoma, derived from primary tumor site, male, 77Y |
VHL−; SETD2− | 58,59 |
769-P | RRID:CVCL_1050 | ATCC® CRL-1933™; CLS #300106 |
Renal cell carcinoma, derived from primary tumor site, female, 63Y |
VHL−; SETD2+ | 60,61 |
ATCC American Type Culture Collection, DZME German Collection of Microorganisms and Cell Culture; ECACC European Collection of Authenticated Cell Cultures, CLS Cell Line Service, COSMIC Catalog of Somatic Mutations in Cancer